trending Market Intelligence /marketintelligence/en/news-insights/trending/e-mv8nw6bgnikaj0fkarww2 content esgSubNav
In This List

Sanofi, Lexicon Pharmaceuticals seek approval for diabetes drug in US, Europe

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Sanofi, Lexicon Pharmaceuticals seek approval for diabetes drug in US, Europe

Sanofi filed a new drug application to the U.S. Food and Drug Administration and a marketing authorization application to the European Medicines Agency for its diabetes drug sotagliflozin.

The company is seeking approval for the drug for use in combination with insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus. Results of a phase 3 trial previously showed that sotagliflozin was better than placebo at treating type 1 diabetes.

Sanofi and Lexicon Pharmaceuticals Inc. are jointly developing the drug under a collaboration and license agreement signed in November 2015.